MBX Biosciences
- Market cap
- 2.63B
- P/E (TTM)i
- -23.01
- P/Bi
- 6.41
- EPSi
- -2.38
- Div yieldi
- 0.00%
- 52W posi
- 70%
Anonymous reader poll. Unscientific, not investment advice.
Shares of MBX Biosciences closed at 54.54, down 4.18%. The company carries a market value of roughly 2.63B, the #2567 most valuable US-listed company we track. The 7 analysts covering the stock are, on balance, at Buy, targeting an average of 99.29 (+82%). Over the past year the stock has ranged from 12.94 to 72.64; it now sits 70% up that band.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 1% of the universe, above its 200-day average.
- Signal has read BUY for 2 weeks.
- Recent price momentum is +116.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -27.8% | Better than 5% |
| Return on invested capital | -31.3% | Better than 3% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -5.6% | Better than 39% |
| 6-month return | 93.9% | Better than 96% |
| 12-month return (ex latest month) | 279.6% | Better than 99% |
| Distance below 52-week high | 19.4% | Better than 48% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 24.6x | Better than 99% |
| Debt to assets | 0.2% | Better than 99% |
| Interest coverage | -68.9x | Better than 3% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 69.6% | Better than 91% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 56.92
- Open
- 56.38
- Day range
- 53.36 - 58.50
- Avg price
- 54.85
- Volume
- 357.16K
- Turnover
- 19.59M
- Turnover ratei
- 1.15%
- Volume ratioi
- 0.70
- Amplitudei
- 9.03%
- 52-week rangei
- 12.94 - 72.64
Valuation
- P/Ei
- -22.92
- P/E (TTM)i
- -23.01
- P/Bi
- 6.41
- EPSi
- -2.38
- Book value / shi
- 8.50
- Net profit
- -114.62M
- Net assets
- 409.55M
Share structure
- Market cap
- 2.63B
- Float capi
- 1.69B
- Shares out
- 48.16M
- Float sharesi
- 30.99M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2024-09-13
24.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-6.28M net over the window
Short interest
- Shares short
- 4.13M
- % of floati
- 8.58%
- Days to coveri
- 11.44
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of MBX Biosciences (MBX)?
MBX Biosciences last traded at 54.54. The quote on this page refreshes every few seconds while US markets are open.
What is MBX Biosciences's market cap?
About 2.63B.
What is the P/E ratio of MBX Biosciences?
The trailing twelve-month P/E is -23.01. The Valuation tab shows it against the stock's own five-year range.
Does MBX Biosciences pay a dividend?
MBX Biosciences does not currently pay a regular dividend.
Is MBX Biosciences a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 99.29, which implies 82.0% upside from the current price. This is not investment advice.
What is MBX Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates MBX Biosciences a B (Buy). Twelve-month momentum in the top 1% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-07 23:20:28 · For reference only, not investment advice and not tailored to your situation.